<DOC>
	<DOCNO>NCT02098460</DOCNO>
	<brief_summary>To evaluate effect concomitant administration Probucol Cilostazol ( base Atorvastatin treatment ) atherosclerosis relate marker ( include thickness Achilles tendon ) severe hypercholesterolemia subject , observation thickness Achilles tendon , thickness mean carotid intima-media , anti-oxidation biomarkers serum lipid profile .</brief_summary>
	<brief_title>To Compare Effect Concomitant Administration Probucol Cilostazol With Probucol Single Treatment Atherosclerosis Related Markers ( Including Thickness Achilles Tendon ) Evaluate Safety ( Based Atorvastatin Treatment ) Severe Hypercholesterolemia Subject</brief_title>
	<detailed_description>Multicenter , randomize , control , single-blinded , three parallel arm study . Group A : Atorvastatin + Probucol-placebo + Cilostazol-placebo Group B : Atorvastatin + Probucol + Cilostazol-placebo Group C : Atorvastatin + Probucol + Cilostazol</detailed_description>
	<mesh_term>Hypercholesterolemia</mesh_term>
	<mesh_term>Atorvastatin Calcium</mesh_term>
	<mesh_term>Probucol</mesh_term>
	<mesh_term>Cilostazol</mesh_term>
	<criteria>1 . The subject whose voluntary write informed consent obtain participation study ; 2 . 18≤age≤70； 3 . The subject lowdensity lipoprotein cholesterol ( LDLC ) ≥ 4.66 mmol/L ( 180 mg/dL ) ( high level either pretreatment treatment ) ; 4 . The subject ATT≥9mm . 1 . The subject homozygous familial hyperlipidemia ; 2 . The subject take Probucol within 6 month screen test ; 3 . The subject take Cilostazol within 1 month screen test ; 4 . The subject take Ezetimibe within 1 month screen test ; 5 . The subject hop treat Ezetimibe within study period ; 6 . The subject treat Cyclosporine ; 7 . The subject history hypersensitivity Probucol Cilostazol ; 8 . The subject triglyceride ( TG ) level great 4.52 mmol/L ( 400 mg/dL ) ; 9 . The subject diabetes : HbA1c level great 8.4 % ( NGSP ) ; 10 . The subject New York Heart Association ( NYHA ) classification : Class III IV ; 11 . The subject QTc interval great 450 msec ( male ) 470 msec ( female ) ; 12 . The subject serious ventricular arrythmias ( frequent episode multifocal ventricular extrasystole ) ; 13 . The subject atrial fibrillation ( include paroxysmal atrial fibrillation ) ; 14 . The subject congestive cardiac failure unstable angina ; 15 . The subject liver renal function satisfy follow criterion within 28 day prior start investigational medicinal product ( IMP ) administration . AST ≥100 IU/L , ALT≥100 IU/L Serum creatinine ≥1.5 mg/dL ( 133 µmol/L ) 16 . The subject participate another clinical trial ; 17 . Woman pregnancy potential pregnancy , breastfeeding ; 18 . Women childbearing potential agree use appropriate method contraception ; 19 . The subject consider Investigators appropriate participate study reason .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>March 2014</verification_date>
	<keyword>Achilles tendon</keyword>
	<keyword>intima-media thickness</keyword>
</DOC>